MwanzoCGEN • NASDAQ
add
Compugen Ltd
$ 2.24
Baada ya Saa za Kazi:(1.79%)+0.040
$ 2.28
Imefungwa: 13 Mac, 17:50:55 GMT -4 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 2.21
Bei za siku
$ 2.22 - $ 2.35
Bei za mwaka
$ 1.13 - $ 2.38
Thamani ya kampuni katika soko
211.80M USD
Wastani wa hisa zilizouzwa
elfu 299.37
Uwiano wa bei na mapato
5.95
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 67.33M | 4,477.29% |
Matumizi ya uendeshaji wa biashara | 7.75M | -6.35% |
Mapato halisi | 56.84M | 1,029.30% |
Kiwango cha faida halisi | 84.42 | 120.30% |
Mapato kwa kila hisa | 0.60 | 957.14% |
EBITDA | 56.16M | 862.91% |
Asilimia ya kodi ya mapato | 0.00% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 145.64M | 41.05% |
Jumla ya mali | 156.57M | 36.15% |
Jumla ya dhima | 53.84M | -10.39% |
Jumla ya hisa | 102.73M | — |
hisa zilizosalia | 94.55M | — |
Uwiano wa bei na thamani | 2.03 | — |
Faida inayotokana na mali | 110.14% | — |
Faida inayotokana mtaji | 183.79% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Des 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 56.84M | 1,029.30% |
Pesa kutokana na shughuli | — | — |
Pesa kutokana na uwekezaji | — | — |
Pesa kutokana na ufadhili | — | — |
Mabadiliko halisi ya pesa taslimu | — | — |
Mtiririko huru wa pesa | — | — |
Kuhusu
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
10 Feb 1993
Tovuti
Wafanyakazi
75
